Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vertex Pharmaceuticals (VRTX) -- Ignore unavailable to you. Want to Upgrade?

To: Pseudo Biologist who wrote (417)	5/16/2000 10:41:00 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 1169

go to another thread? yeah, sounds good. however, before we depart.... yup, Ciba had Chiron/Cetus, and Sandoz had SyStemix/GTI (without challenge, the biggest of blunders known to the sector). But, did they pull in their horns? No!! They kept doing deals and moving up the learning curve. I have great respect for the story to date. A very different path than Bayer, for instance (and there was only one MLNM shot to play catch up...... :-). Let's not forget..... diagnostics were well managed at Chiron, and there was also good business sense in vaccines (if not scientific sense..... I will NEVER forget having gone to hear a Viagene presentation, just before Chiron bought them, where some of the principals admitted that they were barking up the wrong HIV tree). I love this deal. I'd share MZ's cautious "wait and see", if not for the breadth of the VRTX business plan and the relevant preclinical work to date. For those new to the thread..... PB, biowa and MZ are, without question, among the best 10 biotech investors known to man. And, once again -- review the thread -- we're all left saying "thanks Miljenko!"